Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-escalation of Anti-TNF Therapy in IBD (FREE)
NCT04646187Phase 4Enrolling by invitation
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2021
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 4 trial of infliximab, adalimumab in inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis (UC), sponsored by University Medical Center Groningen. Started Mar 2021; status: enrolling by invitation.
02
Drugs
infliximabadalimumab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04646187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646187.